These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 10444240)

  • 41. Non-sedating antihistamines and cardiac arrhythmia.
    Rankin AC
    Lancet; 1997 Oct; 350(9085):1115-6. PubMed ID: 9343494
    [No Abstract]   [Full Text] [Related]  

  • 42. Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old.
    Milgrom H; Kittner B; Lanier R; Hampel FC
    Ann Allergy Asthma Immunol; 2007 Oct; 99(4):358-63. PubMed ID: 17941284
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator.
    Weiler JM; Bloomfield JR; Woodworth GG; Grant AR; Layton TA; Brown TL; McKenzie DR; Baker TW; Watson GS
    Ann Intern Med; 2000 Mar; 132(5):354-63. PubMed ID: 10691585
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Second-generation antihistamines: the risk of ventricular arrhythmias.
    DuBuske LM
    Clin Ther; 1999 Feb; 21(2):281-95. PubMed ID: 10211532
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Variability of the QTc interval: impact on defining drug effect and low-frequency cardiac event.
    Morganroth J; Brown AM; Critz S; Crumb WJ; Kunze DL; Lacerda AE; Lopez H
    Am J Cardiol; 1993 Aug; 72(6):26B-31B. PubMed ID: 8256752
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new H1-receptor antagonist.
    Chaufour S; Caplain H; Lilienthal N; L'héritier C; Deschamps C; Dubruc C; Rosenzweig P
    Br J Clin Pharmacol; 1999 May; 47(5):515-20. PubMed ID: 10336575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Problems of heart rate correction in assessment of drug-induced QT interval prolongation.
    Malik M
    J Cardiovasc Electrophysiol; 2001 Apr; 12(4):411-20. PubMed ID: 11332559
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety of second generation antihistamines.
    Philpot EE
    Allergy Asthma Proc; 2000; 21(1):15-20. PubMed ID: 10748947
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Torsades de pointes occurring in association with terfenadine use.
    Monahan BP; Ferguson CL; Killeavy ES; Lloyd BK; Troy J; Cantilena LR
    JAMA; 1990 Dec; 264(21):2788-90. PubMed ID: 1977935
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Assessment of the antiobstructive effect of fexofenadine on nasal allergy challenge in patients with seasonal allergic rhinitis.
    Mösges R; Lehmacher W; Pasch N; Vent J
    Asian Pac J Allergy Immunol; 2009 Dec; 27(4):181-90. PubMed ID: 20232572
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular toxicity of antihistamines.
    Smith SJ
    Otolaryngol Head Neck Surg; 1994 Sep; 111(3 Pt 2):348-54. PubMed ID: 7916150
    [TBL] [Abstract][Full Text] [Related]  

  • 52. QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine.
    Delauche-Cavallier MC; Chaufour S; Guérault E; Lacroux A; Murrieta M; Wajman A
    Clin Exp Allergy; 1999 Jul; 29 Suppl 3():206-11. PubMed ID: 10444239
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children.
    Delgado LF; Pferferman A; Solé D; Naspitz CK
    Ann Allergy Asthma Immunol; 1998 Apr; 80(4):333-7. PubMed ID: 9564984
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety profile of fexofenadine HCl: a unique therapeutic option in H1-receptor antagonist treatment.
    Meeves SG; Appajosyula S
    J Allergy Clin Immunol; 2003 Oct; 112(4 Suppl):S69-77. PubMed ID: 14530791
    [TBL] [Abstract][Full Text] [Related]  

  • 55. QT interval prolongation and torsades de pointes due to erythromycin lactobionate.
    Oberg KC; Bauman JL
    Pharmacotherapy; 1995; 15(6):687-92. PubMed ID: 8602374
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis.
    Berger WE; Lumry WR; Meltzer EO; Pearlman DS
    Allergy Asthma Proc; 2006; 27(3):214-23. PubMed ID: 16913264
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Studies into the possible central effects of the H-1 receptor antagonist, fexofenadine.
    Stone BM; Turner C; Mills SL; Nicholson AN
    Int Arch Allergy Immunol; 1999; 118(2-4):338. PubMed ID: 10224436
    [No Abstract]   [Full Text] [Related]  

  • 58. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
    Kühlkamp V; Mermi J; Mewis C; Seipel L
    J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms.
    Stokes JR; Romero FA; Allan RJ; Phillips PG; Hackman F; Misfeldt J; Casale TB
    J Allergy Clin Immunol; 2012 Feb; 129(2):409-12, 412.e1-2. PubMed ID: 22196768
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of the efficacy and safety of olopatadine and fexofenadine compared with placebo in Japanese cedar pollinosis using an environmental exposure unit.
    Enomoto T; Lu HQ; Yin M; Sakoda T; Dake Y; Enomoto K; Ide T; Cheng L
    J Investig Allergol Clin Immunol; 2009; 19(4):299-305. PubMed ID: 19639726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.